Apellis Pharmaceuticals Stock Analysis

Apellis Stock Analysis Notes

About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.03. Apellis Pharmaceuticals had not issued any dividends in recent years. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. For more info on Apellis Pharmaceuticals please contact the company at 617 977 5700 or go to https://www.apellis.com.

Apellis Pharmaceuticals Investment Alerts

Apellis Pharmaceuticals Upcoming and Recent Events

Apellis Largest EPS Surprises

View All Earnings Estimates

Apellis Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Apellis Stock Institutional Investors

Note, although Apellis Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Apellis Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.25 B.

Apellis Profitablity

The company has Profit Margin (PM) of (0.35) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.24.

Management Efficiency

Apellis Pharmaceuticals has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0656) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.

Technical Drivers

As of the 28th of November, Apellis Pharmaceuticals shows the risk adjusted performance of (0.03), and Mean Deviation of 2.51. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apellis Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 34.14 per share. Given that Apellis Pharmaceuticals has information ratio of (0.08), we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Apellis Pharmaceuticals Price Movement Analysis

Apellis Pharmaceuticals Insider Trading Activities

Apellis Pharmaceuticals Outstanding Bonds

Apellis Pharmaceuticals Predictive Daily Indicators

Apellis Pharmaceuticals Corporate Filings

Apellis Pharmaceuticals Forecast Models

Apellis Pharmaceuticals' time-series forecasting models are one of many Apellis Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Apellis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Apellis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Apellis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Apellis Pharmaceuticals. By using and applying Apellis Stock analysis, traders can create a robust methodology for identifying Apellis entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Apellis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Apellis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Apellis Pharmaceuticals stock analysis indicators help investors evaluate how Apellis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Apellis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Apellis Pharmaceuticals stock analysis, traders can identify Apellis Pharmaceuticals position entry and exit signals to maximize returns.

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.